Betta Pharmaceuticals Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Betta Pharmaceuticals Co., Ltd.
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
- Other Names / Subsidiaries
- AnewPharma Company, Ltd.
- Equinox Science, LLC
- Xcovery, Inc.
- Zhejiang Beta Pharma Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.